AI1606公司支持Adnexus生物技术公司与Sanctum公司合并,进行艾滋病毒、SARS-CoV-2治疗。 AI firm 1606 Corp. backs Adnexus Biotechnologies' merger with Sanctum for HIV, SARS-CoV-2 treatments.

一个人工智能领导者1606公司正在投资Adnexus生物技术公司,该公司与圣地治疗公司合并,获得HIV和SARS-CoV-2治疗方法. 1606 Corp., an AI leader, is investing in Adnexus Biotechnologies, which merged with Sanctum Therapeutics to acquire HIV and SARS-CoV-2 treatments. 这次合并将Adnexus的AI药物发现平台与Sanctum的HIV疗法结合起来,提高治疗效率,减少病毒抗药性。 This merger combines Adnexus's AI drug discovery platform with Sanctum's HIV therapies, enhancing treatment efficacy and reducing viral resistance. 这项举措加强了Adnexus在艾滋病毒治疗中的地位,扩大了防治传染病的药物管道。 The move strengthens Adnexus's position in HIV treatments and expands its drug pipeline against infectious diseases.